MET and non-small cell lung carcinoma: Finally, Zhao et al showed that miR-34 mimics enhance erlotinib sensitivity in NSCLC cell lines carrying both primary and acquired resistance to EGFR-TKIs [82], and two further studies confirmed that miR-34a might overcome resistance to EGFR-TKIs by targeting MET and AXL, which are both involved in erlotinib resistance [83–84].